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A Composite C/EBP Binding Site Is Essential for the Activity
of the Promoter of the IL-3/IL-5/Granulocyte-Macrophage
Colony-Stimulating Factor Receptor bc Gene1
Thamar B. van Dijk,2,3 Belinda Baltus,2 Jan A. M. Raaijmakers, Jan-Willem J. Lammers,
Leo Koenderman, and Rolf P. de Groot4
The common b-chain (bc) is the main signaling component of the heterodimeric receptors for IL-3, IL-5, and GM-CSF and is
primarily expressed on myeloid cells. The proximal bc promoter is regulated by GGAA binding proteins, including PU.1, a
hemopoietic specific member of the Ets family. However, it is not likely that PU.1 alone accounts for the myeloid-restricted
expression of the bc subunit. Here we describe the identification of a C/EBP binding enhancer that is located 2 kb upstream of
the transcription start site. The enhancer contains two elements that bind C/EBPa and -b in U937 cells, while C/EBPe is also
bound in extracts of HL-60 cells. Importantly, deletion of the enhancer or mutation of either of one of the C/EBP sites results in
a complete loss of promoter activity in cell lines as well as in primary cells, showing the importance of C/EBP members in bc gene
activation. We further show that PU.1 has to cooperate with C/EBP proteins to induce bc transcription. Since the bc is already
expressed on CD341 cells, these results demonstrate that both C/EBP and PU.1 are not only important for the myeloid-specific
gene regulation at later stages of myeloid differentiation. The Journal of Immunology, 1999, 163: 2674–2680.
H ematopoiesis is a developmental process in which plu-ripotent hemopoietic stem cells proliferate and differen-tiate to lineage-committed progenitors, which eventually
generate all kinds of mature, terminally differentiated blood cells
(1). The multistep processes leading to the differentiation of
CD341 stem cells toward the erythroid, lymphoid, or myeloid lin-
eages are at least in part regulated by a network of cytokines. Of
these, G-CSF, M-CSF, GM-CSF, IL-3, and IL-5 are implicated in
the development of myeloid cells, which include monocytes/mac-
rophages and the neutrophilic, eosinophilic, and basophilic gran-
ulocytes (2). Where IL-3 and GM-CSF act on early progenitors,
IL-5, G-CSF, and M-CSF stimulate the late differentiation of eo-
sinophilic, neutrophilic, and monocytic lineages, respectively
(2–4).
Although IL-5, IL-3, and GM-CSF all have distinct effects on
different target cells, they elicit similar responses in cells respon-
sive to all three cytokines, and they even cross-compete for bind-
ing to the same cell (5, 6). Molecular cloning of the receptor com-
ponents and reconstitution of the functional receptors have
revealed that the receptors for the three cytokines are heterodimers
composed of a cytokine-specific a-chain (IL-3Ra, IL-5Ra, and
GM-CSFRa) and a common signaling b-chain (bc)5 (7–9). Both
the a- and b-chains are glycosylated proteins and members of the
class I cytokine receptor family (10). Although the human bc sub-
unit has no binding capacity by itself, it associates with the low
affinity a-chains to form a high affinity receptor (11–13). Besides
its role in high affinity binding, the bc chain plays a major role in
IL-3-, IL-5-, and GM-CSF-mediated signal transduction, explain-
ing the functional overlap of these cytokines (14). Interestingly,
the mouse has two b subunits, known as bc (AIC2B) and bIL-3
(AIC2A) (15, 16). The mouse bc chain is the common b subunit
for the mouse IL-3, IL-5, and GM-CSF receptors, in analogy with
the human bc. Although bc and bIL-3 have 91% homology at the
amino acid level, bIL-3 binds IL-3 with low affinity and does not
form a high affinity receptor with IL-5Ra and GM-CSFRa, in
contradiction to bc (17). We previously reported the cloning of the
human bc gene and the remainders of a bc pseudogene, suggesting
a loss of bIL-3 in the human rather than a murine-specific gene
duplication (18).
In both the human and murine systems, binding of IL-3/IL-5/
GM-CSF induces receptor multimerization, most likely in a ligand:
a:b stoichiometry of 2:2:2 (19). This leads to the activation of
JAK2 (20), a protein tyrosine kinase that is constitutively associ-
ated with the membrane-proximal region of the bc chain (21).
Subsequently, signaling molecules of several signal transduction
pathways are activated, including STAT5 (22, 23), p21Ras (24),
ERK1/2 (25), JNK/SAPK (26), p38 (27), and PI3K (28, 29; for a
review, see Ref. 30). Because the bc subunit is involved in IL-3,
IL-5, and GM-CSF signaling, expression of the bc chain is im-
portant for all myeloid cells and their precursors. Therefore, elu-
cidating the factors that govern its expression will help to under-
stand the events that regulate myeloid lineage commitment.
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The bc chain is already expressed on hemopoietic CD341 stem
cells (31), while at later stages of differentiation expression of the
bc chain is mainly restricted to the myeloid lineages (31). Uncov-
ering the molecular mechanisms that drive its expression will con-
tribute to understanding of the events of myeloid commitment and
differentiation. In the last few years it has become clear that PU.1,
a hemopoietic-specific member of the Ets family, and the C/EBP
family are key transcription factors in myeloid-specific gene acti-
vation (32). Receptors that play a significant role in myeloid de-
velopment, such as GM-CSFRa, G-CSFR, and M-CSFR, have all
been shown to be regulated by the combination of PU.1 and C/EBP
proteins (33–35). Previous studies described the isolation of the
genes for the human and murine bc/bIL-3 subunits (18, 36). We
have shown that PU.1 and another, unidentified GGAA binding
protein activate the human bc gene by binding to the proximal
promoter region (at 265 and 245 bp relative to the transcription
start site, respectively) (18). PU.1, a hemopoietic-specific member
of the Ets transcription factor family (37), is expressed in myeloid
and B cells and has been shown to regulate a number of myeloid
specific genes, including M-CSFR (33), G-CSFR (34), GM-
CSFRa (35), eosinophil-derived neurotoxin (38), myeloperoxidase
(39), and PU.1 itself (40). Other factors that have been shown to be
important for myeloid-specific promoter regulation are members
of the CCAAT/enhancer binding protein (C/EBP) family. Mem-
bers of the C/EBP family have been shown to have a changing
temporal expression pattern during myeloid differentiation.
C/EBPa is expressed at high levels in early progenitors; C/EBPb
and -d become more prominent at later stages, while C/EBPe is
only expressed during granulopoiesis (41–43). C/EBPa, a basic
region leucine zipper transcription factor, originally characterized
in liver and adipose tissue (44), is expressed in early myeloid pre-
cursors (41) and has also been shown to be important for the ex-
pression of M-CSFR, G-CSFR, and GM-CSFRa (33–35). Another
C/EBP member that is important for myeloid gene expression is
C/EBPe, which was recently described to be strongly induced dur-
ing granulocytic differentiation (42, 43). Gene targeting of both
C/EBPa and C/EBPe results in impaired granulopoiesis (45, 46),
clearly demonstrating their roles in myeloid development.
Here we show that, analogous to M-CSFR, G-CSFR, and GM-
CSFRa, the bc is regulated by C/EBP members. We identified a
crucial enhancer located 2 kb upstream of the transcription start
site that contains two C/EBP-binding motifs. Both sites are able to
bind C/EBPa, -b, and -e, while mutation of the sites results in a
complete loss of promoter activity.
Materials and Methods
Cells, cDNAs, oligonucleotides, and Abs
COS-1 cells were cultured in DMEM (Life Technologies, Gaithersburg,
MD) supplemented with 8% heat-inactivated FCS (Life Technologies).
The monocytic cell line U937 and the promyelocytic leukemia cell line
HL-60 were maintained in RPMI 1640 (Life Technologies) supplemented
with 8% FetalClone I (HyClone, Logan, UT).
CD341 cells were isolated from cord blood and differentiated as de-
scribed by Caldenhoven et al. (47). In short, mononuclear cells were ob-
tained by centrifugation of the blood on a Ficoll-Hypaque gradient (den-
sity, 1.077 g/ml). Mononuclear cells were incubated with CD341 Ab and
magnetic beads before positive selection on a column that was placed in a
magnetic field. Cells were cultured in IMDM (Life Technologies) supple-
mented with 10% FCS, stem cell factor (100 ng/ml), FLT-3 ligand (100
ng/ml), IL-3 (0.1 nmol/l), GM-CSF (0.1 nmol/l), and IL-5 (0.1 nmol/l).
After 3 days, cells were cultured in IMDM supplemented with 10% FCS,
IL-3, and IL-5. From day 21, IL-3 was also omitted from the medium.
Viability remained .95% throughout the 28-day experiment.
Human C/EBPa (a gift from Dr. G. W. M. Swart, University of
Nijmegen, The Netherlands), hC/EBPb (a gift from Prof. S. Akira, Hyogo
College of Medicine, Nishinomoya, Japan), human C/EBPg (cloned by
PCR from HL-60 cDNA), rat C/EBPd (a gift from Prof. S. L. McKnight,
Johns Hopkins University, Baltimore, MD), human C/EBPe (cloned by
PCR from HL-60 cDNA), and PU.1 (a gift from Prof. R. M. Maki, Burn-
ham Institute, La Jolla, CA) were cloned into the expression vector pLNCX
(Clontech, Palo Alto, CA).
The following oligonucleotides were used in this study: for PCR cloning
of C/EBPg, gF (59-TGGCAAGGGAGAGTGCCCAA-39) and gR (59-TGA
GGTCTACTG-TCCTGCAT-39);forcloningofC/EBPe,eF(59-TCAAGAGCA
GTGGGGGCGGG-39) and eR (59-TCCACCAGCCAGCCTCAGCT-39); for
site-directed mutagenesis of C/EBP site 1, ENHC1 mut (59-AACTCAAAG
GGGGGGCCCACATGAAGGGTA-39); for C/EBP-site 2, ENHC2 mut (59-
CTCTGTATTTTGCTCGAGTTTCAGAATAAA-39); and for band-shift
analysis (only upper strand is shown), C1 wt (59-AGCTTCAAAGGGGGTTTC
CACATGAAGGGA-39), C1 mut (59-AGCTTCAAAGGGGGGGCCCACAT
GAAGGGA-39), C2 wt (59-AGCTTGCTCTGTATTTTGAAATAGTTTC
AA-39), C2 mut (59-AGCTTGCTCTGTATTTTGCTCGAGTTTCAA-39),
and 265 (59-AGCTTCCGGCACTGCTTCCTCTTTCTGCTA-39).
The following Abs were used in this study: anti-C/EBPa (rabbit poly-
clonal IgG 14AA, sc-061X; Santa Cruz Biotechnology, Santa Cruz, CA),
anti-C/EBPb (rabbit polyclonal IgG C-19, sc-150X; Santa Cruz Biotech-
nology), anti-C/EBPd (rabbit polyclonal IgG M-17, sc-636X; Santa Cruz
Biotechnology), anti-C/EBPe (rabbit polyclonal IgG C-22, sc-158X; Santa
Cruz Biotechnology), and anti-Fli-1 (rabbit polyclonal IgG C-19, sc-356X;
Santa Cruz Biotechnology).
Plasmids for promoter analysis, transient transfection, and CAT
assay
The 2.7-kb HindIII fragment of the bc subunit promoter (22096/1600)
was cloned into the HindIII site of the promoterless pBLCAT3 vector (48).
Deletion construct 21967/1600CAT3 was generated by cloning the Hin-
cII-HindIII fragment (21967/1600) into XbaI and XhoI sites of pBLCAT3
via the SmaI-HindIII sites of SK- (Stratagene, La Jolla, CA), The 129-bp
HindIII-HincII fragment (22096 to 21967) was cloned into the HindIII
and BamHI sites of pBLCAT2 (48) and the HindIII and PstI sites of
TATACAT (49) to generate HH129CAT2 and HH129TATA, respectively,
via the HindIII and SmaI sites of a modified pSG5 (Stratagene). The Bgl2
site at 2289 was used to generate 22096/2289CAT2 and 21967/
2289CAT2. Site-directed mutagenesis was performed according to the
method of Kunkel (50).
For transfection experiments, COS-1 cells were cultured in six-well
dishes (Nunc, Copenhagen, Denmark), and 3 h later the cells were trans-
fected with 6 mg of supercoiled plasmid DNA as described previously (51).
Following 16- to 20-h exposure to the calcium phosphate precipitate, me-
dium was refreshed. Cells were harvested for CAT assays 24 h later. Trans-
fection of U937, HL-60, eosinophils, and neutrophils was performed by
electroporation at 300 V and 960 mF (107 cells, 20 mg of supercoiled
plasmid DNA). In cotransfection experiments 10 mg of promoter construct
was transfected with 10 mg of cDNA. Two days after transfection cells
were harvested for CAT assays. CAT assays were performed as follows.
Cells were lysed by repeated freeze-thawing in 250 mM Tris (pH 7.4) and
25 mM EDTA. Cellular extract was then incubated in a total volume of 200
ml containing 250 mM Tris (pH 7.4), 2% glycerol, 0.3 mM butyryl coen-
zyme A (Sigma, St. Louis, MO), and 0.05 mCi of [14C]chloramphenicol
(Amersham, Arlington Heights, IL) for 2 h at 37°C. Reaction products
were then extracted using 400 ml of xylene/pristane (1/2), and the percent-
age of acetylated products was determined using liquid scintillation count-
ing. All experiments were performed at least four times. A lacZ reporter
was used to correct for transfection efficiency.
Gel retardation assay
Nuclear extracts were prepared from U937 and HL-60 cells following a
previously described procedure (52). Oligonucleotide probes were labeled
by filling in the cohesive ends with [a-32P]dCTP using Klenow fragment
of DNA polymerase I. Gel retardation assays were performed as follows.
Nuclear extracts (10 mg) were incubated in a final volume of 30 mL con-
taining 10 mM Tris (pH 7.4), 10% glycerol, 2 mM EDTA, 50 mM NaCl,
0.05% Nonidet P-40, 300 mg/ml BSA, 30 mg/ml poly(dI/dC), 0.5 mM
DTT, and 1.0 ng of 32P-labeled probe for 20 min at room temperature.
Complexes were then separated through nondenaturing 5% polyacrylamide
gels and were visualized by autoradiography. In competition experiments,
a 10- to 100-fold molar excess of wt or mut oligonucleotide was added to
the reaction mix for 5 min before addition of the labeled probe. For su-
pershift analysis, nuclear extracts were preincubated with 2 mg of Ab for
40 min on ice before addition of the labeled probe.
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Results
A 2-kb upstream enhancer regulates bc subunit expression
In a previous study we reported the isolation of a 2.7-kb HindIII
fragment that contains the 44-bp exon 1, 2096 bp of upstream
sequences, and 598 bp of the first intron of the human bc subunit
gene (18). After cloning into the promoterless pBLCAT3 reporter
plasmid (22096/1600CAT3), transfection experiments in mono-
cytic U937 cells and promyelocytic leukemia HL-60 cells showed
that this fragment contains a functionally active promoter. To lo-
calize cis-activating elements, successive 59 deletion constructs
were generated. The NdeI (at 2566), EcoRI (at 21120), and SmaI
(at 21334) sites were used to generate 2566/1600CAT3, 21120/
1600CAT3, and 21334/1600CAT3, respectively. As shown in
Fig. 1A, these constructs completely lost their activity. Also, con-
struct 21967/1600CAT3, made by using the HincII site at
21967, has no promoter activity, suggesting that an important pos-
itively regulating element has to be present between 22096 and
21967 bp. To test this hypothesis, the 129-bp HindIII-HincII frag-
ment, as well as the fragments from 22096 to 2289 bp and from
21967 to 2289 bp were cloned into the pBLCAT2 vector, a re-
porter plasmid containing the minimal thymidine kinase promoter
(48). The generated constructs, 22096/21967CAT2, 22096/
2289CAT2, and 21967/2289CAT2, were then transfected into
U937 cells and HL-60 cells and tested for promoter activity. Fig.
1B shows that 22096/2289CAT2 is active in both cell types,
while 21967/2289CAT2 has lost this capacity. Indeed, 22096/
21967CAT2 is highly active in both cell types, clearly demon-
strating the presence of an enhancer between 22096 and
21967 bp.
The enhancer contains two C/EBP binding motifs
To localize potential transcription factor binding sites, the 129-bp
enhancer sequence (Fig. 2A) was subjected to the TFMATRIX
transcription factor database (http://pdap1.trc.rwcp.or.jp/research/
db/TFSEARCH.html). As shown in Fig. 2A, one NF-kB and two
C/EBP binding sites were identified. Because C/EBP family mem-
bers play an important role in the constitutive and inducible ex-
pression of a number myeloid-specific genes, the putative C/EBP
sites (C1 and C2, Fig. 2A) were studied in further detail. Band-shift
analysis was used to investigate whether C1 and C2 were protein
binding elements. Oligonucleotide probes, each spanning a single
C/EBP site, were end labeled and incubated with 10 mg of U937
and HL-60 nuclear extract. Fig. 2B shows that elements C1 and C2
are both able to bind a partially overlapping set of protein com-
plexes (lanes 1 and 8). The binding of most complexes could be
competed by addition of a 10- to 100-fold molar excess of cold self
oligo (lanes 2 and 3 and lanes 9 and 10), but not with mutant C1
(lanes 4 and 5), mutant C2 (lanes 11 and 12), or nonrelated 265
oligo (lanes 6 and 7 and lanes 13 and 14), a sequence that spe-
cifically binds transcription factor PU.1 in HL-60 and U937 cells.
One complex (indicated by an arrow) can also be competed with
the mutated or nonrelated oligos. These results demonstrate the
specificity of the complexes binding to elements C1 and C2, except
for the indicated complex. To further characterize the proteins
binding to C1 and C2, the nuclear extracts were preincubated with
specific Abs against C/EBP members and Fli-1, a member of the
Ets family. In HL-60 cells, supershifted complexes appear when
extracts are incubated with anti-C/EBPa, -b, and -e (Fig. 2C, lanes
2, 3, and 5 for C1; lanes 8, 9, and 11 for C2), but not with anti-
C/EBPd (lanes 4 and 10) and anti-Fli-1 control Ab (lanes 6 and
12). Preincubation with anti-C/EBPd (lanes 4 and 10) results in the
disappearance of a complex (indicated by an arrow). It is not clear
whether this complex is C/EBPd, because competition experiments
(see above) suggested that this is a nonspecific complex. Almost
identical results were obtained with U937 cells, but no supershift
was observed when extracts were incubated with anti-C/EBPe (our
unpublished observations). Taken together, these results show that
different C/EBP proteins, including C/EBPa, -b, and -e can bind to
two distinct elements in the upstream enhancer.
The C/EBP sites are essential for enhancer activity
To elucidate whether the C/EBP binding elements are functionally
important, both C1 and C2 were mutated in the 22096/
21967CAT2 construct and tested for promoter activity in U937
and HL-60 cells. Single mutation of either C1 or C2 reduced pro-
moter activity to the background level (Fig. 3A), as occurs when
both sites are mutated. These data show that both elements are
essential for enhancer activity and suggest the cooperation of the
proteins binding to the elements. Next, we cotransfected the wt and
mut constructs with the cDNAs of several C/EBP family members.
Probably due to a cryptic C/EBP site in the pBLCAT2 vector,
cotransfection of C/EBP cDNAs with pBLCAT2 resulted in mod-
erately enhanced background values (3). Therefore, the enhancer
FIGURE 1. An upstream enhancer is crucial for bc promoter activity. A,
U937 and HL-60 cells were transfected with successive 59 deletion con-
structs of the bc promoter cloned in the promoterless pBLCAT3 reporter.
Two days after transfection, cells were harvested, and CAT activity was
determined. Construct 22096/1600CAT3, which is active in both cell
types, contains the 44-bp exon 1, 2096 bp of upstream sequences and 598
bp of the first intron. Deletion of 129 bp at the 59 end results in the com-
plete loss of promoter activity. B, Constructs that lack the proximal pro-
moter, with (22096/2289) and without (21967/2289) the enhancer, and
the isolated enhancer (22096/21967) were cloned into the pBLCAT2 vec-
tor, which contains the minimal thymidine kinase promoter. Deletion of the
enhancer element again results in the loss of promoter activity, while the
isolated enhancer element has maximal CAT activity. This figure demon-
strates that the fragment from 22096 to 21967 bp contains a functionally
important enhancer element. Bars indicate the mean value of at least three
independent experiments. The SD is indicated by error bars.
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constructs were cloned into the pLT-G plasmid, a CAT vector with
a synthetic TATA box. Fig. 3B shows that C/EBPa, -b, -d, and -e
induced a 4- to 5-fold induction of CAT activity when cotrans-
fected with the wt 22096/21967 construct in HL-60 cells (similar
results were obtained in U937 cells; not shown). When C/EBP
elements C1 and C2 were mutated, the effect of C/EBP cotrans-
fection was dramatically decreased. The trans-activating capacity
of C/EBPd is of interest, because it is unclear whether this
protein binds to the enhancer in a band-shift assay (see above).
Nevertheless, C/EBPd binds to C1 and C2 when overexpressed
in COS cells (4).
To further demonstrate the importance of C/EBPs for enhancer
activity, the 22096/21967CAT2 construct was also cotransfected
with C/EBPg, a dominant negative C/EBP member (53), and with
an antisense construct of C/EBPa. As shown in Fig. 3C, cotrans-
fection of antisense C/EBPa reduces promoter activity by 65% in
U937 cells and by 50% in HL-60 cells, while C/EBPg reduces
promoter activity by 70% in both cell types. These results clearly
demonstrate the role of C/EBP proteins in regulation of the bc
chain gene.
To demonstrate that the C/EBP sites also contribute to bc pro-
moter activity in primary cells as opposed to tumor cell lines, we
transfected the C1 and C2 double mutant in the 22096/
21967CAT2 construct into in vitro differentiated eosinophils and
neutrophils (see Materials and Methods). As we found for HL-60
and U937 cells (see Fig. 3A), mutation of the C/EBP sites signif-
icantly reduces enhancer activity in both eosinophils and neutro-
phil (Fig. 3D). This clearly shows that these C/EBP sites are in-
volved in bc promoter activity in primary cells.
C/EBP and PU.1 cooperate to activate the bc promoter in
nonhemopoietic cells
We have previously shown that binding of PU.1 to a GGAA ele-
ment at 265 bp relative to the transcription start site is crucial for
bc chain expression. To more precisely elucidate the roles of PU.1
and C/EBP in bc chain expression, these factors were cotrans-
fected with different promoter constructs in COS fibroblasts. Fig.
4A shows that both PU.1 and C/EBPa enhanced the promoter ac-
tivity of the full promoter construct 22096/1600CAT3 by about
10-fold. However, cotransfection of C/EBPa together with PU.1
resulted in a 30-fold increase in promoter activity. As expected,
C/EBPa could no longer activate transcription when the C/EBP
enhancer was deleted (construct 21967/1600CAT3; Fig. 4A).
Surprisingly, PU.1 could no longer activate this construct. This
was not due to a PU.1 binding site in the 22096/21967 sequence,
because Fig. 4B shows that cotransfection of PU.1 did not affect
the activity of construct 22096/21967CAT2, which is in contrast
to cotransfection of C/EBPa. Construct 2226/133CAT3, which
contains only the promoter proximal region, can only be induced
by PU.1, not by C/EBPa (Fig. 4B, second panel). If trans-activa-
tion of the full promoter construct (22096/1600CAT3) by PU.I is
dependent on proteins binding to the C/EBP sites, this would sug-
gest that COS cells contain endogenous binding activity for the
C/EBP sites. Therefore, we performed band-shift experiments with
FIGURE 2. Two elements in the enhancer bind C/EBP-containing complexes. A, The 150-bp nucleotide sequence of the 59 end of construct 22096/
1600. The 129-bp HindIII/HincII fragment was subjected to a transcription factor database; one NF-kB site and two C/EBP binding elements (C1 and C2,
underlined) were identified. Nucleotides that were mutated to inhibit C/EBP binding are indicated in boldface. B, Nuclear extracts of HL-60 cells were
incubated with oligonucleotides spanning a single C/EBP site and analyzed in a band-shift assay. Elements C1 and C2 bind a partially overlapping set of
complexes (lanes 1 and 8), which can be competed with a 10- to 100-fold molar excess of cold self oligo (lanes 2 and 3 and lanes 9 and 10). When mutant
(C1 mut and C2 mut) or nonrelated oligo (265, a PU.1 binding element) is used, only one complex is competed for binding (indicated by the arrow). C,
Before addition of the labeled oligo, 2 mg of the indicated Ab was added to nuclear extracts of HL-60 cells. Preincubation with Abs against C/EBPa, -b,
and -e, but not with control Ab against Fli-1, results in the appearance of supershifted complexes (lower panel). The upper panel is a shorter exposure of
the same gel. The arrow indicates the complex that disappears when anti-C/EBPd is added. It is unclear whether this complex contains C/EBPd, because
A suggests that this is a nonspecific complex. This figure shows that the enhancer contains two discrete elements that specifically bind C/EBPa, -b, and
-e in HL-60 nuclear extracts. In U937 cells similar results were obtained, but no binding of C/EBPe was detected.
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COS nuclear extracts. Indeed, binding site C2 binds a specific
protein complex in COS cells that can be competed with access
unlabeled probe, but not with a mutated C2 sequence or an unre-
lated oligonucleotide (Fig. 4C). We did not observe specific bind-
ing activity for C1 in COS cells (data not shown). Taken together,
these results indicate that PU.1 and C/EBP functionally cooperate
to enhance bc expression, although their respective binding
elements are not clustered as is described for the GM-CSFRa,
G-CSFR, and M-CSFR promoters.
Discussion
Members of the C/EBP family have been shown to have a chang-
ing temporal expression pattern during myeloid differentiation.
C/EBPa is expressed at high levels in early progenitors, C/EBPb
and -d become more prominent at later stages, while C/EBPe is
only expressed during granulopoiesis (41–43). Alternative splic-
ing and the ability of all members of the C/EBP family to form
homo- and heterodimers lead to a variety of possible DNA binding
complexes. It is likely that these complexes have specific affinities
for particular binding sites and that this mechanism plays an im-
portant role in the specific regulation of certain genes by C/EBPs.
In the bc subunit enhancer we identified two different binding sites
that bind multiple C/EBP containing complexes (Fig. 2, A and B).
Both elements bind C/EBPa, -b, and -e in HL-60, while in U937
cells, which express C/EBPe at a very low level, only binding of
C/EBPa and -b was observed. Binding of C/EBPd is unclear. In a
band-shift assay, addition of anti-C/EBPd Ab results in the disap-
pearance of a specific DNA binding complex. However, the same
complex can be competed with mut and nonrelated oligonucleo-
tides, suggesting that this is a nonspecific binding complex. On the
other hand, C/EBPd from transfected COS cells can bind both sites
(5), and C/EBPd can trans-activate the bc promoter in cotransfec-
tion experiments (Fig. 3B). Experiments with murine embryonic
stem cells and blastocysts have shown that transcription of bc and
bIL-3 is induced at the same time as the CD34 gene (54). In
CD341 cells, the C/EBPa is the predominant expressed isoform
(55) and, therefore, is likely to be involved in the initial induction
of the bc subunit gene(s). Nevertheless, expression of bc/bIL-3 is
unaffected in C/EBPa-deficient mice, while expression of the G-
CSFR is completely blocked (45). This might indicate that C/EBP
members can compensate for each other in some, but not all,
situations.
We have shown that both sites can bind C/EBP independently
and that both sites are functional. Mutation of either site results in
almost a complete loss of promoter activity in cell lines as well as
FIGURE 3. Enhancer activity is mediated via the C/EBP binding sites. A, C/EBP elements C1and C2 were mutated alone (m1 and m2, respectively)
or together (m1–2) in the 22096/21967CAT2 construct and tested for activity in a CAT assay in both U937 and HL-60 cells. Single mutation of either
one of the sites reduces CAT activity to the background level in both cell types. B, Cotransfection in HL-60 cells of the wt 22096/21967 construct with
cDNAs encoding C/EBPa, -b, -d, and -e results in a 4- to 5-fold increase in CAT activity compared with that in the empty pLNCX (pL) vector. The double
mutant is not responsive to C/EBP cotransfection. For this experiment the constructs were cloned into the pLT-G reporter, because C/EBP cotransfection
has a moderate effect on empty pBLCAT2 vector. Similar results were obtained in U937 cells. C, Cotransfection of C/EBPg, a C/EBP member that lacks
the trans-activation domain, or antisense C/EBPa significantly reduces promoter activity of 22096/21967CAT2 in both U937 and HL-60 cells. This figure
shows that the C/EBP elements are responsive to C/EBPa and -e and are both crucial in promoter activation. Bars indicate the mean value of at least three
independent experiments. The SD is indicated by error bars. D, C/EBP elements C1and C2 were mutated both (m1–2) in the 22096/21967CAT2 construct
and tested for activity in a CAT assay in eosinophils and neutrophils differentiated in vitro from CD341 cells isolated from cord blood. The C/EBP elements
clearly contribute to bc promoter activity in primary eosinophils and neutrophils.
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in primary eosinophils and neutrophils (Fig. 3, A and D), suggest-
ing that both sites are crucial for transcription activation. However,
it is not clear whether both sites are occupied by C/EBP simulta-
neously in vivo. Transcription could be reduced by cotransfection
of C/EBPg, a dominant negative C/EBP member, and antisense
C/EBPa, further demonstrating the specific binding of C/EBP pro-
teins to the enhancer sequence (Fig. 3C).
Cotransfection experiments with different deletion constructs
showed the cooperation of C/EBP proteins and PU.1 in the regu-
lation of the bc gene (Fig. 4), reinforcing the significance of these
transcription factors in myeloid development. The combination of
C/EBPs and PU.1 is also important for G-CSFR, GM-CSFRa, and
M-CSFR expression. Functional elements for both proteins have
been identified in the proximal promoters of these genes. The sites
for PU.1 and C/EBP are separated by 15 bp (GM-CSFRa), 35 bp
(M-CSFR), or 85 bp (G-CSFR), indicating that both proteins are
likely to interact. Furthermore, both elements are close to the tran-
scription start site (,100 bp) (33–35). In the bc subunit promoter
the situation is different. Two functional GGAA elements are
present in the proximal promoter region, while important C/EBP
binding sequences are located 2 kb upstream. When isolated, the
PU.1-binding proximal promoter sequence has a high activity
(construct 2226/133; Fig. 4). Interestingly, in the full promoter
context (construct 22096/1600), this activity is dependent on the
C/EBP binding enhancer, because deletion of the enhancer (con-
struct 21967/1600) results in the complete loss of promoter ac-
tivity. This again suggests an interaction between C/EBPs and
PU.1. Why binding of PU.1 is not enough to induce promoter
activity of construct 21967/1600 is not known. Initial experi-
ments opened the possibility that additional, yet unidentified pro-
teins play a role in bc gene activation. It is possible that this fac-
tor(s), PU.1, and C/EBP all have to be present to obtain a
transcriptionally active complex, while in the absence of C/EBP
the additional protein blocks transcription by PU.1. Although fu-
ture experiments are necessary to identify possible additional pro-
moter elements and/or proteins that are involved in bc subunit
expression, we have shown that both PU.1 and C/EBP play a crit-
ical role in bc chain transcription.
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